Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Myelofibrosis and JAK1[original query] |
---|
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr 123 (14): 2157-60. Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M, , |
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British journal of haematology 2018 7 183 (1): 35-46. Palandri Francesca, Catani Lucia, Bonifacio Massimiliano, Benevolo Giulia, Heidel Florian, Palumbo Giuseppe A, Crugnola Monica, Abruzzese Elisabetta, Bartoletti Daniela, Polverelli Nicola, Bergamaschi Micaela, Tiribelli Mario, Iurlo Alessandra, Breccia Massimo, Cavazzini Francesco, Tieghi Alessia, Binotto Gianni, Isidori Alessandro, Martino Bruno, D'Adda Mariella, Bosi Costanza, Sabattini Elena, Vitolo Umberto, Aversa Franco, Ibatici Adalberto, Lemoli Roberto M, Sgherza Nicola, Cuneo Antonio, Martinelli Giovanni, Semenzato Giampietro, Cavo Michele, Vianelli Nicola, Sapienza Maria R, Latagliata Rober |
Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood cancer journal 2018 3 8 (3): 29. Tefferi Ayalew, Barraco Daniela, Lasho Terra L, Shah Sahrish, Begna Kebede H, Al-Kali Aref, Hogan William J, Litzow Mark R, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Pardanani Anime |
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood advances 2017 Sep 1 (20): 1729-1738. Spiegel Jay Y, McNamara Caroline, Kennedy James A, Panzarella Tony, Arruda Andrea, Stockley Tracy, Sukhai Mahadeo, Thomas Mariam, Bartoszko Justyna, Ho Jenny, Siddiq Nancy, Maze Dawn, Schimmer Aaron, Schuh Andre, Sibai Hassan, Yee Karen, Claudio Jamie, Devlin Rebecca, Minden Mark D, Kamel-Reid Suzanne, Gupta Vik |
MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clinical lymphoma, myeloma & leukemia 2022 9 22 Suppl 2 S334. Masarova Lucia, Bose Prithviraj, Pemmaraju Naveen, Kantarjian Hagop, Estrov Zeev, Verstovsek Srd |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: